This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
KK8398 will be administered.
Aichi Children's Health and Medical Center
Ōbu, Aichi-ken, Japan
RECRUITINGOsaka University Hospital
Suita, Osaka, Japan
RECRUITINGOsaka Women's and Children's Hospital
Waizumi, Osaka, Japan
Change from baseline in annualized height velocity
Time frame: Pre-dose, Week 52
Height Z-score using growth tables in patients with achondroplasia and the change from baseline
Time frame: Pre-dose, Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tokyo Metropolitan Children's Medical Center
Fuchū, Tokyo, Japan
RECRUITINGTottori University Hospital
Yonago, Tottori, Japan
RECRUITINGNiigata University Medical and Dental Hospital
Niigata, Japan
RECRUITINGOkayama University Hospital
Okayama, Japan
RECRUITINGISEIKAI International General Hospital
Osaka, Japan
RECRUITINGOsaka City General Hospital
Osaka, Japan
RECRUITING